Goldman Sachs’s Verrica Pharmaceuticals VRCA Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $92.9K | Buy |
175,284
+36,229
| +26% | +$19.2K | ﹤0.01% | 4894 |
|
|
2025
Q1 | $61.5K | Buy |
139,055
+26,308
| +23% | +$11.6K | ﹤0.01% | 4895 |
|
|
2024
Q4 | $78.9K | Buy |
112,747
+32,191
| +40% | +$22.5K | ﹤0.01% | 4812 |
|
|
2024
Q3 | $117K | Buy |
+80,556
| New | +$117K | ﹤0.01% | 4588 |
|
|
2024
Q2 | – | Sell |
-19,555
| Closed | -$116K | – | 4931 |
|
|
2024
Q1 | $116K | Buy |
+19,555
| New | +$116K | ﹤0.01% | 4439 |
|
|
2023
Q4 | – | Sell |
-13,857
| Closed | -$53.8K | – | 4941 |
|
|
2023
Q3 | $53.8K | Sell |
13,857
-7,738
| -36% | -$30.1K | ﹤0.01% | 4479 |
|
|
2023
Q2 | $125K | Sell |
21,595
-48,570
| -69% | -$280K | ﹤0.01% | 4526 |
|
|
2023
Q1 | $456K | Buy |
+70,165
| New | +$456K | ﹤0.01% | 4117 |
|
|
2022
Q4 | – | Sell |
-17,594
| Closed | -$51K | – | 5367 |
|
|
2022
Q3 | $51K | Sell |
17,594
-14,156
| -45% | -$41K | ﹤0.01% | 5034 |
|
|
2022
Q2 | $61K | Buy |
31,750
+20,948
| +194% | +$40.2K | ﹤0.01% | 5238 |
|
|
2022
Q1 | $88K | Buy |
+10,802
| New | +$88K | ﹤0.01% | 5348 |
|
|
2020
Q1 | – | Sell |
-33,393
| Closed | -$531K | – | 4569 |
|
|
2019
Q4 | $531K | Buy |
33,393
+8,139
| +32% | +$129K | ﹤0.01% | 3626 |
|
|
2019
Q3 | $373K | Buy |
+25,254
| New | +$373K | ﹤0.01% | 3703 |
|
|
2018
Q3 | – | Sell |
-50,714
| Closed | -$1M | – | 4246 |
|
|
2018
Q2 | $1M | Buy |
+50,714
| New | +$1M | ﹤0.01% | 3199 |
|